05/24/23 8:36 AMNasdaq : OCGN offeringOcugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common StockOcugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the pricing of its underwritten public offering of 30,000,000 sharesRHEA-AIneutral
05/23/23 4:01 PMNasdaq : OCGN offeringOcugen, Inc. Announces Proposed Public Offering of Common StockOcugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it has commenced an underwritten public offering of its commonRHEA-AIneutral
05/23/23 8:00 AMNasdaq : OCGN conferencesOcugen to Present at BIO International Convention 2023Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present at the 2023 BIORHEA-AIneutral
05/05/23 7:00 AMNasdaq : OCGN earningsOcugen Provides Business Update with First Quarter 2023 Financial ResultsConference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Received Orphan Drug Designation (ODD) from the FDA for OCU410ST forRHEA-AIneutral
04/28/23 7:00 AMNasdaq : OCGN conferencesearningsOcugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial ResultsOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call andRHEA-AIneutral
04/27/23 7:25 AMNasdaq : OCGN Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated RetinopathiesOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology companyRHEA-AIvery positive
04/26/23 6:30 AMNasdaq : OCGN conferencesOcugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor ConferenceOcugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman,RHEA-AIneutral
04/20/23 8:00 AMNasdaq : OCGN conferencesOcugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual MeetingOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present on itsRHEA-AIneutral
04/14/23 7:45 AMNasdaq : OCGN clinical trialOcugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital AmaurosisFavorable safety and tolerability profile related to OCU400 investigational product candidate Initial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes 71.4% (5/7) of OCU400RHEA-AIpositive
04/11/23 6:20 PMNasdaq : OCGN conferencesOcugen to Host Virtual Investor & Analyst Event on April 14, 2023Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology companyRHEA-AIneutral